Andere Sprachen Nykode Therapeutics

Aktien

A2PZ5J

NO0010714785

VACC

Markt geschlossen - Oslo Bors Andere Börsenplätze 16:45:00 26.06.2024			% 5 Tage	% 1. Jan.
14,77 ^NOK	+3,07 %		+1,72 %	-30,98 %

20.06.	Nykode Therapeutics gibt auf dem FOCIS 2024 Meeting Updates zu seiner inversen Impfstoffplattform bekannt	CI
11.06.	Nykode Therapeutics ASA gibt bekannt, dass der mRNA-LNP-Krebsimpfstoff eine überlegene Wirksamkeit zeigt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Nykode Therapeutics : Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20.06.
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting	20.06.
Nykode Therapeutics : presentation from ABGSC Seminar on Autoimmunity, Transplantation & Inflammation	11.06.
Nykode Therapeutics ASA Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy	11.06.
Nykode Therapeutics : Q1 2024 Financial Results – presentation	14.05.
Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Nykode Therapeutics : Q1 2024 Financial Results	14.05.
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer	14.05.
Nykode Therapeutics : reports Q1 2024 Financial Results	14.05.
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	19.04.
Nykode Therapeutics : Remuneration Report 2023	19.04.
Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	19.04.
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer	21.03.
Nykode Therapeutics ASA Announces Advances in the Inverse Vaccine Platform with the Potential to Treat Autoimmune Diseases	19.03.
Nykode Therapeutics AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Nykode Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Nykode Therapeutics Announces Expansion of Oncology Pipeline Aiming to Reduce the Burden of Colorectal Cancer	14.12.
Nykode Therapeutics AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15.11.
Nykode Therapeutics - Mandatory notification of acquisition of shares by primary insider	27.10.23
Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding	25.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nykode Therapeutics

Aktien

A2PZ5J

NO0010714785

VACC

Andere Sprachen

Filter